Skip to main content
Fig. 4 | Journal of Biomedical Science

Fig. 4

From: Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer

Fig. 4

Effects of myricetin and enzalutamide alone and in combination. C4-2B cells were treated with indicated concentrations of the drugs (M, myricetin; Enza, enzalutamide; M + Enza: the combination of myricetin and enzalutamide). The ratio of Myricetin/enzalutamide is [IC50]Myricetin/[IC50]enzalutamide based on the Chou-Talalay method [39]. Cell viability was measured using the MTT assay, the non-linear regression trendline analysis of IC50 values was calculated by Prism7 and the CI values were generated by CompuSyn

Back to article page

Journal of Biomedical Science

ISSN: 1423-0127